CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.

Item
http://www.wikidata.org/entity/Q53224139
Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2V617F mutations and laboratory findings: a meta-analysis.Significance of combined detection of JAK2V617F, MPL and CALR gene mutations in patients with essential thrombocythemiaScreening PCR Versus Sanger Sequencing: Detection of CALR Mutations in Patients With ThrombocytosisThe Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.Progenitor genotyping reveals a complex clonal architecture in a subset of CALR-mutated myeloproliferative neoplasms.The relevance of a low JAK2V617F allele burden in clinical practice: a monocentric studyCharacterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative NeoplasmsImproved survival in patients with CALR1 compared to CALR2 mutated primary myelofibrosis: a meta-analysis.Clinical and hematological relevance of JAK2 V617F and CALR mutations in BCR-ABL-negative ET patients.Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis.The myeloproliferative neoplasms, unclassifiable: clinical and pathological considerations.High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance.Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
P2860

CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.

Item
http://www.wikidata.org/entity/Q53224139
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@en
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@nl
type
label
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@en
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@nl
prefLabel
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@en
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@nl
P1433
P1476
P2093
P304
P31
P356
P407
P433
P478
P577
P698
P356
P1433
P1476
CALR, JAK2, and MPL mutation p ...... tive neoplasm, unclassifiable.
@en
P2093
P304
P31
P356
P407
P433
P478
P577
P698